Man Group’s Aimmune Therapeutics AIMT Stock Holding History

Man Group’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-777,492	Closed	-$26.8M	–	2020
2020 Q3	$26.8M	Buy	+777,492	New	+$16.6M	0.11%	209
2019 Q4	–	Sell	-34,314	Closed	-$719K	–	1967
2019 Q3	$719K	Buy	+34,314	New	+$701K	﹤0.01%	1506
2019 Q2	–	Sell	-73,779	Closed	-$1.65M	–	2082
2019 Q1	$1.65M	Buy	+73,779	New	+$1.74M	0.01%	1408
2018 Q4	–	Sell	-16,550	Closed	-$451K	–	2210
2018 Q3	$451K	Buy	16,550 +11,014	+199%	+$312K	﹤0.01%	1867
2018 Q2	$149K	Buy	+5,536	New	+$169K	﹤0.01%	2048

Man Group's AIMT Position: Q4 2020 in Review

Man Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 777,492 shares — an estimated $26.8M sold.

Man Group first reported a position in AIMT in Q2 2018 and held it in 5 quarters. The position peaked at $26.8M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Man Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Man Group sold 777,492 Aimmune Therapeutics shares in Q4 2020, an estimated $26.8M.
Man Group first reported a position in Aimmune Therapeutics in Q2 2018 and held it in 5 quarters.
Man Group's Aimmune Therapeutics position peaked at $26.8M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Man Group's 13F filing for Q4 2020, filed 16 Feb 2021.